Amwill Healthcare Limited is one of India's fastest-growing companies in the dermatology, trichology, and cosmetology sectors. Specializing in advanced active dermatology products, Amwill’s offerings are based on natural ingredients, allopathic actives, and special techniques to ensure visible, effective results. The company is set to launch its IPO for ₹59.97 Crores, consisting of a fresh issue of 44.03 lakh shares worth ₹48.87 Crores and an Offer for Sale (OFS) of 10 lakh shares worth ₹11.1 Crores.

The Amwill Healthcare IPO opens on February 5, 2025, and closes on February 7, 2025. The IPO allotment is expected to be finalized on February 10, 2025, with listing scheduled on February 12, 2025 on the BSE SME.

Price Range and Lot Size:

• The IPO price range is set between ₹105 to ₹111 per share.
• The market capitalization at the highest IPO price (₹111 per share) is ₹222.04 Crores.
• Lot size is 1,200 shares, requiring a minimum investment of ₹1,33,200 for retail investors. High-Net-Worth Individuals (HNIs) are required to invest in 2 lots, totaling ₹2,66,400.

Amwill Healthcare IPO Subscription and Allotment:

As of 11:00 AM on February 5, 2025, the IPO has been subscribed 0.16 times on its first day. Investors should keep an eye on the live subscription status as the offering progresses. The IPO allotment status will be available on the Registrar's website starting February 10, 2025. Investors can check the allotment status by entering their application number, PAN, or DP Client ID.

Objectives and Use of IPO Proceeds:

Amwill Healthcare intends to use the net proceeds from the IPO for the following:

• ₹2,500 Lakhs for funding the company’s working capital requirements.
• ₹500 Lakhs for marketing and brand-building activities.
• General corporate purposes.

Financial Performance and IPO Review:

Amwill Healthcare has experienced steady growth in revenue, with FY24 revenues reported at ₹2,324.71 Lakhs, up from ₹2,761.54 Lakhs in FY22. The EBITDA for FY24 stands at ₹893.04 Lakhs, reflecting strong operational efficiency. The Profit after Tax (PAT) for FY24 was ₹651.66 Lakhs, demonstrating profitability and growth.

The EPS for FY24 stands at ₹8.04 pre-issue, which decreases to ₹6.27 post-issue. The P/E ratio for the IPO is 13.81x pre-issue and 17.71x post-issue, significantly lower than the industry average of 36x. The company’s Return on Capital Employed (ROCE) for FY24 is 94.16%, while the Return on Equity (ROE) and Return on Net Worth (RoNW) both stand at 73.06%. These financial indicators suggest the company has solid growth potential.

Amwill Healthcare IPO Grey Market Premium (GMP):

The Grey Market Premium (GMP) of Amwill Healthcare is reported to be ₹0, indicating no significant pre-listing trading. It is important to note that GMP is not a reliable indicator of actual listing performance and can fluctuate based on market demand and supply.

IPO Subscription and Listing Expectations:

With a GMP of ₹0, Amwill Healthcare IPO is not expected to see significant listing gains in the short term. Therefore, we recommend avoiding the IPO for listing gains and suggest long-term investors consider the company’s growth trajectory in the dermatology sector.

The Upcoming IPOs in this week and coming weeks are  Readymix Construction, Solarium Green, Eleganz Interiors, PS Raj Steels, Chandan Healthcare, Ajax Engineering.

The Current active IPO are Ken Enterprises, Amwill Healthcare,Chamunda Electricals.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.